Clinical trial · Interventional
Improving Cognition and Behavior in Pediatric Cancer Survivors Using a Novel Mindful Attention Training
A Pilot Study of Assessing and Improving Cognition and Real-World Behavior in Pediatric Cancer Survivors
NCT05000905CI-TRIAL-00093183withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Slow accrual
Summary
Brief summary (as posted)
This pilot study will evaluate the cognitive and behavioral outcomes of using a novel, adaptive attention training in pediatric cancer survivors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pediatric Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Adaptive Attention Training | Behavioral | — | UNRESOLVED |
| Questionnaires | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Adaptive Attention Training
- description
- Participants will complete approximately 15 hours of an at-home training on a novel adaptive attention training program ('Engage'), which will consist of completing thirty, 30-minute sessions over a total of 6-8 weeks.
- interventionNames
- Behavioral: Adaptive Attention Training
- Behavioral: Questionnaires
- type
- ACTIVE_COMPARATOR
- label
- Low-dose Adaptive Attention Training
- description
- Participants will complete approximately 1 hour of at-home training on 'Engage' which consists of two, 30-minute sessions at the beginning and middle of a 6-8 week period.
- interventionNames
- Behavioral: Adaptive Attention Training
- Behavioral: Questionnaires
- type
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 7 Years
- Maximum age
- 17 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 7-17 at the time of enrollment. 2. Able to understand study procedures and to comply with them for the entire length of the study. 3. Ability of individual and legal guardian/representative to understand a written informed consent document, and the willingness to sign it. 4. Normal or corrected-normal vision and hearing. 5. English language fluency (minor participant and parent/guardian). 6. Received radiation therapy to the brain or neck between age 7-17. 7. Patients not on current cancer-related treatment (except supportive care) or those on other current treatments that would not hinder study participation. Patients currently on cancer-related treatments will be discussed with the study team (co-PI Mueller). Exclusion Criteria: 1. Contraindication to any study-related procedure or assessment. 2. Motor/perceptual difficulties that prevent computer or tablet use. 3. Current cancer-related treatments that would impact the ability to participate in the study (e.g., current inpatient chemotherapy or intrathecal chemotherapy). Patients on other current treatments will be discussed with the study team (co-PI, Dr. Mueller)
References
Publications (0)
Data not yet available
No reference posted for this study.